Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Apr;37(4):363–369. doi: 10.1111/j.1365-2125.1994.tb04290.x

Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man.

N M Wheeldon 1, D G McDevitt 1, B J Lipworth 1
PMCID: PMC1364737  PMID: 7912539

Abstract

The aim of the present study was to evaluate the cardiac effects of the beta 3-adrenoceptor agonist BRL35135, and determine whether beta 3-receptors are involved in mediating chronotropic or inotropic responses in man. Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors. Both BRL and SAL produced a significant increase in postural finger tremor in keeping with beta 2-adrenoceptor stimulation, and this response was totally abolished by pretreatment with N20. Significant increases in systolic blood pressure and Doppler stroke distance occurred with BRL and SAL which were unaffected by pretreatment with B5 and completely blocked by N20, in keeping with beta 2-mediated effects. BRL and SAL produced significant chronotropic and minute distance responses which were unaffected by beta 1-adrenoceptor blockade. However, whereas N20 blocked these responses to SAL, a small but significant response occurred with BRL in comparison with placebo despite complete blockade of co-existing beta 2-mediated effects. Compared with PL, the mean responses to N20/BRL, and the 95% confidence interval for the differences between the means were 7.4 beats min-1 [3.2 to 11.6] (P = 0.002) for heart rate, and 208.8 cm [38.3 to 379.3] (P = 0.02) for minute distance responses.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
363

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arch J. R., Ainsworth A. T., Cawthorne M. A., Piercy V., Sennitt M. V., Thody V. E., Wilson C., Wilson S. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature. 1984 May 10;309(5964):163–165. doi: 10.1038/309163a0. [DOI] [PubMed] [Google Scholar]
  2. Arnold J. M., McDevitt D. G. Reflex vagal withdrawal and the hemodynamic response to intravenous isoproterenol in the presence of beta-antagonists. Clin Pharmacol Ther. 1986 Aug;40(2):199–208. doi: 10.1038/clpt.1986.164. [DOI] [PubMed] [Google Scholar]
  3. Arnold J. M., O'Connor P. C., Riddell J. G., Harron D. W., Shanks R. G., McDevitt D. G. Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol. 1985 May;19(5):619–630. doi: 10.1111/j.1365-2125.1985.tb02689.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blue D. R., Bond R. A., Adham N., Delmendo R., Michel A. D., Eglen R. M., Whiting R. L., Clarke D. E. Antagonist characterization of atypical beta adrenoceptors in guinea pig ileum: blockade by alprenolol and dihydroalprenolol. J Pharmacol Exp Ther. 1990 Mar;252(3):1034–1042. [PubMed] [Google Scholar]
  5. Brodde O. E. Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev. 1991 Jun;43(2):203–242. [PubMed] [Google Scholar]
  6. Challiss R. A., Leighton B., Wilson S., Thurlby P. L., Arch J. R. An investigation of the beta-adrenoceptor that mediates metabolic responses to the novel agonist BRL28410 in rat soleus muscle. Biochem Pharmacol. 1988 Mar 1;37(5):947–950. doi: 10.1016/0006-2952(88)90186-4. [DOI] [PubMed] [Google Scholar]
  7. Chandraratna P. A., Nanna M., McKay C., Nimalasuriya A., Swinney R., Elkayam U., Rahimtoola S. H. Determination of cardiac output by transcutaneous continuous-wave ultrasonic Doppler computer. Am J Cardiol. 1984 Jan 1;53(1):234–237. doi: 10.1016/0002-9149(84)90718-5. [DOI] [PubMed] [Google Scholar]
  8. Emorine L. J., Marullo S., Briend-Sutren M. M., Patey G., Tate K., Delavier-Klutchko C., Strosberg A. D. Molecular characterization of the human beta 3-adrenergic receptor. Science. 1989 Sep 8;245(4922):1118–1121. doi: 10.1126/science.2570461. [DOI] [PubMed] [Google Scholar]
  9. Esbenshade T. A., Han C., Theroux T. L., Granneman J. G., Minneman K. P. Coexisting beta 1- and atypical beta-adrenergic receptors cause redundant increases in cyclic AMP in human neuroblastoma cells. Mol Pharmacol. 1992 Nov;42(5):753–759. [PubMed] [Google Scholar]
  10. Granneman J. G., Lahners K. N., Chaudhry A. Molecular cloning and expression of the rat beta 3-adrenergic receptor. Mol Pharmacol. 1991 Dec;40(6):895–899. [PubMed] [Google Scholar]
  11. Haites N. E., McLennan F. M., Mowat D. H., Rawles J. M. Assessment of cardiac output by the Doppler ultrasound technique alone. Br Heart J. 1985 Feb;53(2):123–129. doi: 10.1136/hrt.53.2.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hall J. A., Petch M. C., Brown M. J. Intracoronary injections of salbutamol demonstrate the presence of functional beta 2-adrenoceptors in the human heart. Circ Res. 1989 Sep;65(3):546–553. doi: 10.1161/01.res.65.3.546. [DOI] [PubMed] [Google Scholar]
  13. Heitz A., Schwartz J., Velly J. Beta-adrenoceptors of the human myocardium: determination of beta 1 and beta 2 subtypes by radioligand binding. Br J Pharmacol. 1983 Dec;80(4):711–717. doi: 10.1111/j.1476-5381.1983.tb10062.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hollenga C., Haas M., Deinum J. T., Zaagsma J. Discrepancies in lipolytic activities induced by beta-adrenoceptor agonists in human and rat adipocytes. Horm Metab Res. 1990 Jan;22(1):17–21. doi: 10.1055/s-2007-1004839. [DOI] [PubMed] [Google Scholar]
  15. Kaumann A. J. Is there a third heart beta-adrenoceptor? Trends Pharmacol Sci. 1989 Aug;10(8):316–320. doi: 10.1016/0165-6147(89)90065-5. [DOI] [PubMed] [Google Scholar]
  16. Lipworth B. J., Brown R. A., McDevitt D. G. Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade. Br J Clin Pharmacol. 1989 Jul;28(1):95–102. doi: 10.1111/j.1365-2125.1989.tb03510.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lipworth B. J., Irvine N. A., McDevitt D. G. A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol. 1991;40(2):135–139. doi: 10.1007/BF00280067. [DOI] [PubMed] [Google Scholar]
  18. Lipworth B. J., McDevitt D. G. Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol. 1989;36(3):239–245. doi: 10.1007/BF00558154. [DOI] [PubMed] [Google Scholar]
  19. McLaughlin D. P., MacDonald A. Characterization of catecholamine-mediated relaxations in rat isolated gastric fundus: evidence for an atypical beta-adrenoceptor. Br J Pharmacol. 1991 Jun;103(2):1351–1356. doi: 10.1111/j.1476-5381.1991.tb09792.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Newnham D. M., Wheeldon N. M., Lipworth B. J., McDevitt D. G. Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects. Thorax. 1993 Jun;48(6):656–658. doi: 10.1136/thx.48.6.656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Northridge D. B., Findlay I. N., Wilson J., Henderson E., Dargie H. J. Non-invasive determination of cardiac output by Doppler echocardiography and electrical bioimpedance. Br Heart J. 1990 Feb;63(2):93–97. doi: 10.1136/hrt.63.2.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pringle T. H., Riddell J. G., Shanks R. G. Characterization of the beta-adrenoreceptors which mediate the isoprenaline-induced changes in finger tremor and cardiovascular function in man. Eur J Clin Pharmacol. 1988;35(5):507–514. doi: 10.1007/BF00558246. [DOI] [PubMed] [Google Scholar]
  23. Rimoy G. H., Bhaskar N. K., Rubin P. C. Reproducibility of Doppler blood flow velocity waveform measurements: study on variability within and between day and during haemodynamic intervention in normal subjects. Eur J Clin Pharmacol. 1991;41(2):125–129. doi: 10.1007/BF00265904. [DOI] [PubMed] [Google Scholar]
  24. Strauss M. H., Reeves R. A., Smith D. L., Leenen F. H. The role of cardiac beta-1 receptors in the hemodynamic response to a beta-2 agonist. Clin Pharmacol Ther. 1986 Jul;40(1):108–115. doi: 10.1038/clpt.1986.146. [DOI] [PubMed] [Google Scholar]
  25. Wheeldon N. M., McDevitt D. G., Lipworth B. J. Do beta 3-adrenoceptors mediate metabolic responses to isoprenaline. Q J Med. 1993 Sep;86(9):595–600. [PubMed] [Google Scholar]
  26. Wheeldon N. M., McDevitt D. G., Lipworth B. J. Investigation of putative cardiac beta 3-adrenoceptors in man. Q J Med. 1993 Apr;86(4):255–261. [PubMed] [Google Scholar]
  27. Wilson C., Wilson S., Piercy V., Sennitt M. V., Arch J. R. The rat lipolytic beta-adrenoceptor: studies using novel beta-adrenoceptor agonists. Eur J Pharmacol. 1984 May 4;100(3-4):309–319. doi: 10.1016/0014-2999(84)90007-4. [DOI] [PubMed] [Google Scholar]
  28. de Vente J., Bast A., Van Bree L., Zaagsma J. beta-Adrenoceptor studies. 6. Further investigations on the hybrid nature of the rat adipocyte beta-adrenoceptor. Eur J Pharmacol. 1980 Apr 11;63(1):73–83. doi: 10.1016/0014-2999(80)90118-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES